Radiochemistry and Preclinical PET Imaging of 68 Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen

Abstract

Radiotracers incorporating the urea-based Glu-NH-C(O)-NH-Lys group have gained prominence due to their role in targeting prostate-specific membrane antigen (PSMA)—a clinical biomarker of prostate cancer. Here, the synthesis, radiolabeling, and in vitro and in vivo characterization of two ⁶⁸Ga-radiolabeled Glu-NH-C(O)-NH-Lys radiotracers conjugated to the desferrioxamine B (DFO) chelate were evaluated. Two linker groups based on amide bond and thiourea coupling chemistries were employed to develop ⁶⁸Ga-DFO-Nsucc-PSMA (⁶⁸Ga-4) and ⁶⁸Ga-DFO-pNCS-Bn-PSMA (⁶⁸Ga-7), respectively. Radiosynthesis proceeded quantitatively at room temperature with high radiochemical yields, chemical/radiochemical purities, and specific activities. Pharmacokinetic profiles of ⁶⁸Ga-4 and ⁶⁸Ga-7 were assessed using positron-emission tomography (PET) in mice bearing subcutaneous LNCaP tumors. Data were compared to the current clinical benchmark radiotracer ⁶⁸Ga-HBED-CC-PSMA (⁶⁸Ga-1) (HBED = N,N′-Bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine N,N′-diacetic acid). Results indicated that the target binding affinity, protein association, blood pool and background organ clearance properties, and uptake in PSMA-positive lesions are strongly dependent on the nature of the chelate, the linker, and the spacer groups. Protein dissociation constants (K _d values) were found to be predictive of pharmacokinetics in vivo. Compared to ⁶⁸Ga-1, ⁶⁸Ga-4 and ⁶⁸Ga-7 resulted in decreased tumor uptake but enhanced blood pool clearance and reduced residence time in the kidney. The study highlights the importance of maximizing protein binding affinity during radiotracer optimization.

Keywords

gallium-68 prostate-specific membrane antigen (PSMA)positron-emission tomography chelates desferrioxamine

Introduction

Prostate-specific membrane antigen (PSMA; also known as glutamate carboxypeptidase II [GCPII] or N-acetyl-l-aspartyl-l-glutamate peptidase I [NAALADase I]) is an important class II membrane-bound zinc metalloenzyme that catalyzes the hydrolysis of N-acetylaspartylglutamate (NAAG) to glutamate and N-acetylaspatate (NAA).¹ The PSMA has emerged as a valuable preclinical and clinical biomarker of prostate cancer (PCa). Many prostate cancers, as well as other cancers that exhibit neoangiogenesis, express high levels of PSMA. Lower levels are found in physiologically normal tissues such as the kidneys, salivary glands, and small intestine.² Consequently, differential PSMA expression in PCa has led physicians and radiochemists to explore the use of PSMA as a target for delivering a wide range of diagnostic and radiotherapeutic nuclides.^3
–5

Worldwide, at least 50 clinical trials have investigated PSMA-targeted imaging or therapy in different populations of patients with PCa (source: www.clinicaltrials.gov). The two most important classes of drugs targeting PSMA are small-molecule urea-based inhibitors^{4,6

–12} and anti-PSMA antibodies.^13

–18 In terms of molecular imaging with positron-emission tomography (PET), the urea-based ⁶⁸Ga-HBED-CC-PSMA^19

–24 (⁶⁸Ga-1; Figure 1) and antibody-based ⁸⁹Zr-DFO-J591^15

–18 have shown promise for characterizing PSMA profiles in humans. For small-molecule PSMA inhibitors, the excellent clinical performance of ⁶⁸Ga-labeled agents for PET also prompted multicenter studies which demonstrated that ¹⁷⁷Lu-labeled analogues can be used to advance a novel “theranostic” (combined diagnostic imaging and radiotherapy) regimen.^25,26

Figure 1.

Structure of the HBED-CC- prostate-specific membrane antigen (PSMA) ligand (compound 1).

The synthesis and biological evaluation of a large number of Glu-NH-C(O)-NH-Lys inhibitors of PSMA have been reported.^6,27 Many radiolabeled analogues are also studied in vivo. Selected examples include work using the radionuclides fluorine-18,^28

–31 copper-64,^11,32 gallium-68,^19,20,23,33 technetium .99m,^7,9,34 and various radiohalogens.^4,6,35 While recent studies have demonstrated that the performance of at least two ¹⁸F-radiolabeled agents,¹⁸F-DCFPyL²³ and ¹⁸F-PSMA-6,²⁴ and the more recent compound ¹⁸F-PSMA-1007,³⁶ compare favorably to that of ⁶⁸Ga-1; this ⁶⁸Ga-radiotracer remains the most well-characterized radiometal-based agent for PET imaging of PSMA. The radiosynthesis of ⁶⁸Ga-1 is well established—essentially quantitative radiolabeling can be achieved upon reacting the precursor HBED-CC-PSMA (compound 1) with ⁶⁸Ga in sodium acetate buffer at pH 4.5 for 10 minutes at 95°C.^19,20 Interestingly, the use of the HBED chelate has been suggested to lead to the potential formation of two diastereomers as resolved by high-performance liquid chromatography (HPLC).²⁰ The composition ratio of these two species depends on the pH and reaction temperature—data confirming that one isomer is thermodynamically more stable in aqueous solution and that intramolecular hydrogen bonding is likely to influence complex stability. Experimental studies in cells also showed that the two species have identical binding properties toward PSMA.²⁰ However, the formation of two isomers (in a variable ratio²⁰) is unsatisfactory from the perspective of quality control (QC) in a clinical setting.

In this work, we synthesized and evaluated two new ⁶⁸Ga-labeled PSMA inhibitors bearing the tris-hydroxamic acid chelate desferrioxamine B (DFO). Two bifunctional versions of DFO (DFO-Nsucc [2] and DFO-pNCS-Bn [5]; Figure 2) with varying lipophilic character of the linker/spacer group were conjugated to Glu-NH-C(O)-NH-Lys-Ahx starting materials (compounds 3 and 6) to generate the radiolabeling precursors 4 and 7, respectively (Figure 2). Saturation binding assays in LNCaP cells, ex vivo protein binding and stability measurements, and PET imaging were used to compare the two new radiotracers ⁶⁸Ga-DFO-Nsucc-PSMA (⁶⁸Ga-4) and ⁶⁸Ga-DFO-pNCS-Bn-PSMA (⁶⁸Ga-7), to the clinical radiotracer ⁶⁸Ga-1. Results found that targeting of PSMA using urea-based radiometal complexes is highly sensitive to the chemical nature of the chelate and linker/spacer groups.

Figure 2.

Coupling reactions used in the synthesis of desferrioxamine B (DFO)-Nsucc-prostate-specific membrane antigen (PSMA; compound 4) and DFO-pNCS-Bn-PSMA (compound 7).

Materials and Methods

Standard laboratory techniques were employed throughout. Unless otherwise stated, all solvents and reagents were used as received from the supplier (SigmaAldrich [Darmstadt, Germany], TCI Deutschland [Eschborn, Germany], Acros [Geel, Belgium]). The HBED-CC-PSMA (also known as DKFZ-11) was purchased from ABX (Radeberg, Germany). Low-resolution electrospray ionization mass spectrometry ((+)-LR-ESI-MS) was performed on a PerkinElmer Flexar SQ 300 MS Detector (Waltham, MA). High-resolution electrospray ionization mass spectra ((+)-HR-ESI-MS) were measured by the Mass Spectrometry Service at the University of Zurich. HPLC was conducted on an Agilent 1260 Infinity System equipped with an Agilent 1200 DAD UV detector (UV detection at 220 nm) (Santa Clara, CA) equipped with Raytest radiation detector (Raytest GmbH, Straubenhardt, Germany) and a Chromolith Performance RP-18e 100-4.6 mm column (Merck, Billerica, MA). Typically, a water/acetonitrile gradient elution method (1.0 mL/min; 5 minutes; 5%-60% MeCN; UV detection at 220 nm and 320 nm) was used for analytical measurements (Chromolith method). Samples were lyophilized using a Christ Alpha 1-2 LD plus lyophilizer. All instruments measuring radioactivity were calibrated and maintained in accordance with previously reported routine QC procedures.³⁷ Radioactivity measurements were made using a calibrated Activimeter ISOMED 2010 (Nuklear-Medizintechnik, Dresden, Germany). For accurate quantification of radioactivity, experimental samples were counted for between 30 seconds and 1 minute on a calibrated PerkinElmer 2480 Automatic Wizard² Gamma Counter (Perkin Elmer, Waltham, Massachusetts). A dynamic energy window of 400 to 600 keV was used for ⁶⁸ Ga (511 keV emission) detection.

Synthesis

The DFO-Nsucc-PSMA (4)

The DFO was reacted with succinic anhydride in accordance with previously reported methods to give the reagent DFO-Nsucc (2).³⁸ The tris-tBu-protected urea (3) was purchased from ABX and used as received. The tris-tBu-protected urea (3; 5.2 mg, molecular weight [MW] 600.8 g/mol, 9.07 μmol) was dissolved in DMF (200 μL). DFO-Nsucc (2; 6.60 mg, MW 661.7 g/mol, 10.0 μmol) is only sparingly soluble in DMF and was dissolved in dimethyl sulfoxide (DMSO; 200 μL). 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU; 4.0 mg, 1.16 equivalent) was dissolved in DMF (200 μL) to which N, N-diisopropylethylamine (DIPEA; 3.3 μL, 1.9 μmol, 2.1 equivalent) was added. The HATU/DIPEA mixture was added to the solution of compound 2 and then the resulting mixture was added to the solution of compound 3. The reaction was stirred at room temperature for 24 hours and progress was monitored by (+)-LR-ESI-MS. Then the DMF was evaporated and the crude product was deprotected by reaction with a trifluoroacetic acid/triisopropylsilane/water (TFA/TIS/H₂O; 95/2.5/2.5 v/v ratio) mixture (100 μL) for 2 hours at room temperature. The crude product was then precipitated by slow addition of diethyl ether, separated from the supernatant by centrifugation, and dissolved in 30% MeCN/H₂O. The crude product was purified by preparative HPLC on a Macherey-Nagel Nucleosil reverse phase C18 column (Oensingen, Germany) with a 10% to 45% MeCN/H₂O (0.1% TFA v/v added to both solvents) gradient over 12 minutes. On this HPLC system, the product eluted with a retention time (R _t) of 6.6 minutes. The product was lyophilized to give compound 4 as a white amorphous powder (1.6 mg, 1.5 μmol, 16%). The (+)-LR-ESI-MS m/z (30% MeCN/H₂O) 1076 (50%; [M+H]⁺ = C₄₇H₈₄N₁₀O₁₈ ²⁺) and 539 (100%; [M+2 H]²⁺ = C₄₇H₈₄N₁₀O₁₈ ²⁺). The (+)-HR-ESI-MS m/z (30% MeCN/H₂O) found 538.2981 (100%; [M+2 H]²⁺) calculated for C₄₇H₈₄N₁₀O₁₈ ²⁺ = 538.2977.

Test labeling reactions conducted in water at room temperature using compound 4 and nonradioactive ^natGa(NO3)₃ gave the desired product ^natGa-DFO-Nsucc-PSMA (^natGa-4) in solution, with a single peak in reverse-phase (RP) HPLC (10%-45% MeCN/H₂O gradient. R _t = 10.2 minutes; >98%), (+)-LR-ESI-MS m/z (30% MeCN/H₂O) 571 (100%; [M+2 H]²⁺), (+)-HR-ESI-MS m/z (30% MeCN/H₂O) found 571.2491 (100%; [M+2 H]²⁺), calculated for C₄₇H₈₁N₁₀O₁₈Ga²⁺ = 571.2488. Additional test reactions labeling compound 4 with ^natFeCl₃ gave an instantaneous and intense color change from colorless to a deep brown/orange solution, indicating the formation of an Fe-DFO complex of orange/brown with a known broad electronic absorption maximum at 430 nm (∊₄₃₀ = 2216 ± 49 mol/dm³/cm).¹⁶

The DFO-pNCS-Bn-PSMA (7)

Urea (6) was isolated by preparative HPLC after TFA/TIS/H₂O deprotection of tris-tBu-protected urea (3).¹⁹ Urea (6; 1.2 mg, MW 432.5 g mol^-1 _, 2.8 μmol) was dissolved in DMF (250 μL). Separately, DFO-pNCS-Bn (5; Macrocyclics, Dallas, Texas; 2.3 mg, MW 752.8 g/mol, 3.1 μmol, 1.1 equivalent) was dissolved in DMSO (150 μL), and DIPEA (1.1 μL, 0.8 μmol, 2.2 equivalent) was added. Then the solution of compound 5 was added to the solution of compound 6, and the reaction was stirred for 24 hours at room temperature. Reaction progress was monitored by (+)-LR-ESI-MS. The crude reaction was then diluted with 2.1 mL H₂O, and the product was purified by preparative HPLC on a Macherey-Nagel Nucleosil reverse phase C18 column with a 10% to 45% MeCN/H₂O (0.1% TFA v/v added to both solvents) gradient over 25 minutes. On this HPLC system, the product eluted with a retention time R _t of 13.0 to 13.8 min. The product was lyophilized to give compound 7 as a white amorphous powder (2.5 mg, 2.1 μmol, 76%). (+)-LR-ESI-MS m/z (50% MeCN/H₂O) 1186 (30%; [M+H]⁺ = C₅₁H₈₅N₁₂O₁₆S₂ ⁺) and 594 (100%; [M+2 H]²⁺ = C₅₁H₈₆N₁₂O₁₆S₂ ²⁺), (+)-HR-ESI-MS m/z (50% MeCN/H₂O) found 593.2877 (100%; [M+2 H]²⁺) calculated for C₅₁H₈₆N₁₂O₁₆S₂ ²⁺ 593.2863.

Test labeling reactions conducted in water at room temperature using compound 7 and ^natGa(NO3)₃ gave the desired product ^natGa-DFO-pNCS-Bn-PSMA (^natGa-7) in solution with a single peak in RP-HPLC (10-45% MeCN/H₂O gradient, R _t = 10.2 min; >98%), (+)-LR-ESI-MS m/z (30% MeCN/H₂O) 626 (100%; [M+2 H]²⁺ = C₅₁H₈₃GaN₁₂O₁₆S₂ ²⁺).

Radiochemistry

⁶⁸Ga-radiolabeling experiments were conducted either manually or using the Modular-Lab PharmTracer automated synthesis module (Eckert&Ziegler, Berlin, Germany). Briefly, the ⁶⁸Ge/⁶⁸Ga-generator (Eckert&Ziegler, Model IGG100 Gallium-68 Generator) was eluted with HCl (0.1 M, 7 mL) in accordance with the manufacturer’s protocol. The eluate (∼600 MBq) was loaded onto a cation exchange column (Strata-XC [SCX]; Phenomenex, Torrance, California), and ⁶⁸Ga was eluted from the SCX cartridge with 800 μL of a mixture of 0.13 mol/L HCl in ∼5 mol/L NaCl(aq). For all automated syntheses, the ⁶⁸Ga eluate was transferred into the reaction vial containing the appropriate buffer and radiolabeling precursor (vide infra).

Radiosynthesis of ⁶⁸Ga-HBED-CC-PSMA (⁶⁸Ga-1)

⁶⁸Ga-HBED-PSMA (⁶⁸Ga-1)¹⁹ was prepared in 10 minutes at 95°C, using the Modular-Lab PharmTracer module by Eckert & Ziegler (Berlin, Germany). The ⁶⁸Ga eluate (∼600 MBq) was transferred into a preheated reaction vial containing sodium acetate (2 mL, ∼1 mol/L, pH4.5), HCl (∼0.18 mol/L), ascorbic acid (20 μL, 100 mg/mL), and HBED-CC-PSMA (compound 1; 10 μg). The crude reaction mixture was loaded onto a SepPak Light C-18 cartridge (Waters Corporation, Milford, Massachusetts) and then washed with water (10 mL) to remove uncomplexed radiometal ions and polar impurities. The radiotracer was eluted in ∼0.5 mL 50% EtOH/H₂O, and the product was analyzed by RP-HPLC (Chromolith method: R _t = 2.33 (25%) and 2.38 (75%) min.; specific activity A_s = 42.2 GBq/μmol). Note two species (potentially diastereomers) are formed in an approximate ratio of 1:3. These two species are shown to behave in an identical manner toward PSMA binding in vitro and in vivo.²⁰ Typical decay-corrected radiochemical yields (RCYs; including both species) were >98% (n = 5) with radiochemical purity (RCP) >98% (n = 5).

Radiosynthesis of ⁶⁸Ga-DFO-Nsucc-PSMA (⁶⁸Ga-4)

⁶⁸Ga-DFO-Nsucc-PSMA (⁶⁸Ga-4) was prepared within 10 minutes at room temperature by manual synthesis and using the Modular-Lab PharmTracer module by Eckert & Ziegler (Berlin, Germany). The ⁶⁸Ga eluate (∼600 MBq) was transferred into a reaction vial containing ammonium acetate buffer (2.0 mL, 0.5 mol/L, pH5.2) and DFO-Nsucc-PSMA (compound 4; 10-20 μg). After reaction, the crude mixture was loaded onto a SepPak Light C18 cartridge (Waters Corporation) and washed with water (10 mL) to remove uncomplexed radiometal ions and polar impurities. The radiotracer was eluted in ∼0.5 mL 30% EtOH/H₂O, and the product was analyzed by RP-HPLC (Chromolith method: R _t = 2.39 min. (100%); specific activity [A_s] = 27.4 GBq/μmol). Typical decay-corrected RCYs were >98% (n = 8) with RCP >99% (n = 8).

Radiosynthesis of ⁶⁸Ga-DFO-pNCS-Bn-PSMA (⁶⁸Ga-7)

⁶⁸Ga-DFO-pNCS-Bn-PSMA (⁶⁸Ga-7) was prepared using the same procedure describe for ⁶⁸Ga-4 (vide supra). The ⁶⁸Ga-7 radiotracer was eluted from the Sep-Pak Light C18 cartridge in ∼0.5 mL 30% EtOH/H₂O, and the product was analyzed by RP-HPLC (Chromolith method: R _t = 2.57-3.13 minutes (100%); A_s = 23.8 GBq/μmol). Typical decay-corrected RCYs were >96% (n = 8) with RCP >98% (n = 8).

Lipophilicity (LogD) measurements

The lipophilicity values of the ⁶⁸Ga-radiotracers are reported as LogD (n-octanol/phosphate-buffered saline [PBS] pH7.4) and were determined using the standard “shake-flask” method.^39,40

Cells and Tissue Culture

The PSMA-positive LNCaP cells (ATCC, Manassas, Virginia) were cultured at 37°C in a 5% CO₂ atmosphere (RPMI Medium 1640 GlutaMAX containing 1% fetal bovine serum [FBS], 100 U/mL penicillin, 100 μg/mL streptomycin, and sodium–pyruvate 1 mmol/L).

Saturation Binding Experiments In Vitro

For receptor saturation analysis, PSMA(+) LNCaP cells were seeded at a density of 0.8 to 1 million cells per well in 6-well poly-L-lysine (PLL)-coated plates and incubated overnight with medium (RPMI Medium 1640 GlutaMAX containing 1% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 1 mmol/L sodium pyruvate). After 24 hours, the medium was removed, the cells were washed and incubated for 1 hour at 37°C with fresh binding buffer (RPMI Medium 1640 GlutaMAX containing 1% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 50 mmol/L HEPES, 50 μg/mL bacitracin, and 0.5% bovine serum albumin). Then the plates were placed on ice for 30 minutes, followed by incubation with increasing concentrations of ^68/natGa-radiotracers in PBS-binding buffer (pH7.4) for 120 minutes at 4°C. Nonspecific binding was determined in the presence of excess 2-(phosphonomethyl)pentane-1,5-dioic acid (PMPA; 1 μmol/L). The cells were washed twice with ice-cold PBS and then lysed with 1 mol/L NaOH. The cell-associated radioactivity was measured using a gamma counter. Specific binding was plotted against the total molar concentration of the added radiotracer. The K _d/nM values and the concentration of the radiotracers required to saturate the receptors (B _max/nM) were determined by nonlinear regression analysis. In all cellular experiments, the calculated values were normalized to the number of cells per well (typically 1 × 10⁶ cells). Data reported are from 2 independent experiments with triplicate data points in each experiment.

Xenograft Models

All animal experiments were conducted according to the regulations of the University Medical Center of Freiburg, Germany, and in accordance with the principles of the 3Rs and the Guide for the Care and Use of Laboratory Animals. Normal athymic Balb/c nude mice (17-20 g, 4-6 weeks old, n = 12) were obtained from Janvier SAS (St Berthevin Cedex, France). Mice were provided with food and water ad libitum. The LNCaP tumors were induced on the right shoulder by subcutaneous (sc) injection of 5.0 million cells in a 100-μL cell suspension of a 1:1 v/v mixture of media with reconstituted basement membrane (GFR BD Matrigel; Corning BV, Amsterdam, Holland). After an average of 4 weeks, the tumor size reached ∼200 to 300 mg (estimated by caliper measurements), and the animals were then used for PET imaging studies.

Blood Plasma Protein Binding Studies and Metabolism In Vivo

Mice (n = 2/group) were administered with appropriate formulations of the 3 ⁶⁸Ga-radiotracers (7.3-11.1 MBq, 0.3-0.4 nmol in 0.2 mL PBS) via intravenous tail vein injections. Mice were killed 15 minutes post-radiotracer administration. Blood was collected in heparinized tubes and centrifuged (5 minutes, 1700 g) for plasma isolation. Plasma samples (300 mL) were transferred to an ultrafiltration device (Vivacon 500; 30 kDa molecular weight cutoff [Sartorius Stedium Biotech GmbH, Germany]), and centrifuged (10 minutes, 9660 g) to separate proteins. Samples of the filtrate and protein fraction were measured in the gamma counter. In addition, aliquots of the eluate from ultrafiltration were analyzed by RP-HPLC to assess the extent of radiotracer metabolism in the soluble blood component.

Small-Animal PET Imaging

The PET imaging experiments were conducted on a microPET Focus 120 scanner (Concorde Microsystems, Knoxville, Tennessee).⁴¹ For static scans, mice were administered ⁶⁸Ga-radiotracer formulations (15.4-18.7 MBq, ∼0.56-0.68 nmol in 200 µL sterile filtered PBS pH7.4 [Note: the ethanol content was <8% for all formulations]) via intravenous tail vein injection. For dynamic scans, a higher dose of radioactivity (∼28 MBq, ∼0.9-1.0 nmol) was administered to ensure adequate counting statistics during reconstruction of comparatively short timing windows (from between 20 seconds and 5 minutes). Approximately 5 minutes prior to recording PET images, mice were anesthetized by inhalation of 2% to 3% isoflurane/oxygen gas mixture, fitted with an intravenous catheter (dynamic scans), and placed on the scanner bed in the prone position. Anesthesia was maintained using 1% to 2% isoflurane. The PET images were recorded at various time points between 0 and 3 hours postinjection. Dynamic scans were recorded for 3500 seconds postradiotracer administration and temperature was maintained using a heating pad. List-mode data were acquired using a γ-ray energy window of 350 to 650 keV and a coincidence timing window of 6 nanoseconds. The PET sinograms were reconstructed using a 2-dimensional ordered subset expectation maximization algorithm. Image counts per second per voxel were calibrated to activity concentrations (Bq/g) by measuring a 3.5-cm cylinder phantom filled with a known concentration of radioactivity and mass. For quantification of tumor radioactivity uptake in the PET scans, small 3-dimensional volumes-of-interest (VOIs) were drawn manually using AMIDE Medical Image Data Examiner software,⁴² and the decay corrected mean percentage injected dose per gram (%ID/g) in various tissues was determined.

Competitive inhibition (blocking) studies were also performed in vivo using static PET imaging to investigate the specificity of the ⁶⁸Ga-radiotracers for PSMA. Non-radiolabeled PMPA (20 nmol/mouse) was coinjected with the ⁶⁸Ga-radiotracers (n = 3).⁴³

Statistical Analyses

Statistical analyses were performed using GraphPad Prism 5.01 (GraphPad Software, Inc, San Diego, California) and Microsoft Excel (Version 15). Data were analyzed using the unpaired, 2-tailed Student t test. Differences at the 95% confidence level (P < .05) were considered to be statistically significant.

Results and Discussion

Synthesis and Radiochemistry

Ligands 4 and 7 were synthesized using standard amide bond or thiourea chemistries in 16% and 76% yield, respectively. A summary of the in vitro characterization data is presented in Table 1. Both compounds gave single peaks in RP-HPLC with >98% chemical purity. The chemical composition of compounds 4 and 7 was confirmed using both low- and high-resolution electrospray ionization mass spectrometry. For compounds 4 and 7, peaks corresponding to the monoprotonated molecular ion [M+H]⁺ and the diprotonated species [M+2 H]²⁺ were identified in (+)-LR-ESI-MS. In (+)-HR-ESI-MS only peaks corresponding to the [M+2 H]²⁺ ions (at m/z 538.2981 and 593.2877, for 4 and 7, respectively) were found. Subsequent nonradioactive reactions between ligands 4 and 7 with Ga(NO₃)₃ gave the expected peaks at m/z 571 and 626 (100%; [M+2 H]²⁺), respectively. Furthermore, a test reaction between an aqueous solution of ligand 4 and FeCl₃ gave an instantaneous color change from colorless to an intense orange/brown, confirming the formation of the Fe-DFO complex. Note that Fe-DFO has a known broad electronic absorption maximum at 430 nm.¹⁶

Table 1.

Summary of the In Vitro Characterization Data.

Compound	Molecular Formula	MW (calcd) /g/mol^a	Specific activity / GBq/μmol	LogD (n-octanol: PBS pH7.4)	K _d / nmol/L
⁶⁸Ga-1	C₄₄H₅₈GaN₆O₁₇S₂ ^–	1075.2561	42.2	−4.06 ± 0.10	2.89 ± 0.55
⁶⁸Ga-4	C₄₇H₇₉GaN₁₀O₁₈	1140.4830	27.4	−3.24 ± 0.05	26.4 ± 7.8
⁶⁸Ga-7	C₅₁H₈₁GaN₁₂O₁₆S₂	1250.4591	23.8	−2.60 ± 0.02	13.6 ± 2.6

Abbreviations: ⁶⁸Ga-1, ⁶⁸Ga-HBED-CC-PSMA; ⁶⁸Ga-4, ⁶⁸Ga-DFO-Nsucc-PSMA; ⁶⁸Ga-768, Ga-DFO-pNCS-Bn-PSMA; PSMA, prostate-specific membrane antigen.

^aExact isotopic mass.

Manual and fully automated ⁶⁸Ga-radiolabeling reactions were optimized in ammonium acetate buffer (0.5 mol/L, pH 5.2, room temperature). ⁶⁸Ga-radiolabeling of 4 and 7 proceeded quantitatively at room temperature in 10 to 15 minutes. Both radiolabeled compounds ⁶⁸Ga-4 and ⁶⁸Ga-7 were isolated from the reaction mixture using a Sep-Pak Light C18 cartridge (Waters Corporation, Milford, MA). After loading the C18 cartridge, the compounds were purified from unreacted ⁶⁸Ga³⁺ ions by washing with water or saline, and the product was eluted with 20% to 30% EtOH/water (v/v). The average RCYs for ⁶⁸Ga-4 and ⁶⁸Ga-7 were >98% (n = 8) and >96% (n = 8), with RCP >98%, and specific activities of 27.4 and 23.8 GBq/μmol, respectively. In comparison, using a similar automated synthesis module, ⁶⁸Ga-1 was isolated with an A_s of 42.2 GBq/μmol. Notably, when higher amounts of initial ⁶⁸Ga-radioactivity are used in the routine clinical preparation of ⁶⁸Ga-1, A_ss as high as 75 to 80 GBq/μmol can be achieved. When the initial amount of labeling precursors 4 and 7 was reduced from 20 μg to 10 μg, A_ss of ⁶⁸Ga-4 and ⁶⁸Ga-7 increased accordingly and were comparable to that attained for ⁶⁸Ga-1. Both radiolabeled compounds ⁶⁸Ga-4 and ⁶⁸Ga-7 were found to be stable with respect to changes in RCP after incubation in saline or PBS at 37°C for over 4 hours. These data confirmed that no radiolysis or chemical degradation occurred in the formulated samples used for in vitro and in vivo studies.

Lipophilicity measurements for ⁶⁸Ga-1, ⁶⁸Ga-4, and ⁶⁸Ga-7 gave LogD values of −4.06 ± 0.10, −3.24 ± 0.05, and −2.60 ± 0.02, respectively. In comparison to ⁶⁸Ga-1, the new DFO-conjugated compounds are less hydrophilic. Consistent with the chemical structures of the linker groups, measurements showed that the more hydrophilic succinyl linker/spacer in ⁶⁸Ga-4 conveys increased water solubility compared to the aromatic pNCS-Bn group in ⁶⁸Ga-7.

Cellular Assays

Prior to conducting PET imaging in mice, the cellular dissociation constants (K _d/nM) and specificity of ^68/natGa-radiotracers 1, 4, and 7 were measured using standard saturation binding experiments in LNCaP PSMA(+) cells (Table 1 and Figure S1).^16,44,45 Across all experiments, estimated receptor concentrations (B_max values) were consistent in the range 0.27 to 0.41 nmol/L. Cellular binding data confirmed that both ⁶⁸Ga-radiotracers of ligands 4 and 7 bind specifically to PSMA expressed on LNCaP cells. The apparent K _d values of ⁶⁸Ga-4 (26.4 ± 7.8 nmol/L) and ⁶⁸Ga-7 (13.6 ± 2.6 nM) indicate that these compounds exhibit lower affinity toward PSMA than the current clinical radiotracer ⁶⁸Ga-7 (2.89 ± 0.55 nmol/L). Typically, a lower binding affinity of a radiotracer would reduce target tissue uptake in PET imaging. However, it is worth noting that specific contrast in PET is influenced by multiple factors including nonspecific uptake, tissue perfusion, cellular internalization, and sequestration which influences retention/washout, metabolic stability, and whole-body excretion. Therefore, PET imaging in tumor-bearing mice was performed to evaluate radiotracer pharmacokinetics.

Positron-Emission Tomography Imaging in Tumor-Bearing Mice

A combination of dynamic (for 3500s) and static PET scans (starting at 30 minutes, 1, 2, and 3 hours postradiotracer administration) were used to assess the pharmacokinetics and specificity of the ⁶⁸Ga-radiotracers for detecting PSMA expression in mice bearing subcutaneous LNCaP tumors on the right shoulder. Representative static PET images recorded at 1 hour are shown in Figure 3. Additional PET data are presented in Supporting Information Figures S2 to S6. Competitive inhibition studies (blocking using coadministration of PMPA [20 nmol/mouse]⁴³) confirmed the specificity of the ⁶⁸Ga-radiotracers for PSMA expression. Time–activity curves (TACs) of the tumor, heart/blood pool, kidney, and bladder measured from VOI analysis of the dynamic PET data are shown in Figure 4.

Figure 3.

Representative static positron emission tomography (PET) scans of ⁶⁸Ga-HBED-CC- prostate-specific membrane antigen (PSMA)-(⁶⁸Ga-1), ⁶⁸Ga- desferrioxamine B (DFO)-Nsucc-PSMA (⁶⁸Ga-4), and ⁶⁸Ga-DFO-pNCS-Bn-PSMA (⁶⁸Ga-7) recorded at 1 hour postradiotracer administration in mice bearing subcutaneous LNCaP tumors (∼200-300 mg). In each case, blocking studies confirmed the specificity of the ⁶⁸Ga-radiotracer for PSMA expression. Note that in the 3 sets of image data, different upper thresholds (in units of %ID/g) have been used for visual clarity in the representation of radiotracer uptake in the tumors. T indicates tumor; K, kidney; B, bladder.

Figure 4.

Time–activity curves (TACs) of the accumulation and washout of ⁶⁸Ga-radioactivity in (A) the tumor, (B) the heart/blood pool, (C) the kidneys, and (D) the bladder from 0 to 30 minutes postadministration of ⁶⁸Ga-HBED-CC-PSMA (⁶⁸Ga-1; black), ⁶⁸Ga-desferrioxamine B (DFO)-Nsucc-PSMA (⁶⁸Ga-4; blue), and ⁶⁸Ga-DFO-pNCS-Bn-PSMA (⁶⁸Ga-7; red).

Imaging data revealed that the 2 radiotracers, ⁶⁸Ga-4 and ⁶⁸Ga-7, showed specific accumulation in PSMA(+) LNCaP tumors. In the case of ⁶⁸Ga-4, peak uptake (∼3-4%ID/g) was observed within the first 5 to 10 minutes postadministration, after which, rapid washout of the radioactivity occurred. The tumor washout phase for ⁶⁸Ga-4 correlated with decreased activity in the heart/blood pool and excretion via the kidneys/bladder (Figure 4). At later time points (1-3 hours), ⁶⁸Ga-4 tumor uptake/retention showed higher accumulation in tumors than the background due to perfusion (Figures S3 and S4). However, after 3 hours postadministration, absolute tumor uptake of ⁶⁸Ga-4 remained very low (∼0.8-1.2%ID/g).

In dynamic PET, ⁶⁸Ga-7 showed similar peak tumor uptake (∼3.5-4.0%ID/g) to ⁶⁸Ga-4 but overall had a dramatically different pharmacokinetic profile. Heart/blood pool activity of ⁶⁸Ga-7 remained higher at each time point in the dynamic scans, and in contrast to the rapid tumor washout observed for ⁶⁸Ga-4, tumor-associated radioactivity showed slower washout for ⁶⁸Ga-7 (2.90 ± 0.46%ID/g after 3500 seconds). Static PET imaging revealed that tumor-associated ⁶⁸Ga-7 activity was specific and retained at ∼2.5-3.5%ID/g for up to 3 hours (Figures S5 and S6 [blocking study]).

Equivalent dynamic and static PET imaging experiments using the standard clinical agent ⁶⁸Ga-1 showed that this radiotracer has a longer residence time in the heart/blood pool, with considerably higher uptake and retention of radioactivity in both the LNCaP tumors and in the kidneys (Figure 4 and Figure S2). In dynamic scans, ⁶⁸Ga-1 tumor uptake continued to increase to >8.0%ID/g after 3500 seconds.

Interestingly, the 3 ⁶⁸Ga-radiotracer studied displayed completely different pharmacokinetic uptake/excretion profiles (see heart/blood pool, kidney and bladder TACs in Figure 4). The TACs showed that each of the ⁶⁸Ga-radiotracers was extracted from the blood. However, ⁶⁸Ga-4 was most rapidly cleared from circulation, followed by ⁶⁸Ga-7 and then ⁶⁸Ga-1. Clearance is predominantly via a urinary mechanism, and the radiotracers showed specific binding to the kidney (which is known to express PSMA). Kidney TACs confirmed the differences in the behavior of the 3 ⁶⁸Ga-radiotracers (Figure 4C). Specifically, ⁶⁸Ga-4 showed a very rapid influx and efflux from the kidney, concordant with low affinity binding to PSMA and a rapid clearance to the bladder. In contrast, ⁶⁸Ga-7 displayed a broader and more prolonged residence in the kidney tissue with a peak uptake of ∼50%ID/g at ∼1400 seconds postadministration followed by a slow washout phase. The clinical radiotracer, ⁶⁸Ga-1, displayed rapid accumulation in the kidney with a maximum around 30%ID/g at ∼500 seconds postadministration which was retained for the duration of the dynamic scans. Pharmacokinetic profiles of ⁶⁸Ga-1 in kidney and bladder are consistent with rapid and specific binding of the radiotracer to the available PSMA. The TAC data suggest that after ∼500 seconds postradiotracer administration of ⁶⁸Ga-1, an equilibrium is reached between uptake and clearance in the kidney. Bladder TACs are consistent with conclusion Figure 4D. The tumor uptake, kidney binding, and bladder excretion profiles of ⁶⁸Ga-1, ⁶⁸Ga-4, and ⁶⁸Ga-7 are consistent with the measured cellular dissociation constants (K _d values; Table 1).

Plasma Protein Binding and Metabolic Stability

To address differences in the pharmacokinetic profiles observed for the 3 ⁶⁸Ga-radiotracer, ex vivo plasma protein binding and metabolite analyses were conducted using size-exclusion and HPLC methods. Radiotracers were injected into groups of mice and blood samples (n = 2/radiotracer) were taken at 15 minutes postradiotracer administration. Plasma proteins were separated from the soluble component by ultrafiltration and radioactivity counted (Figure 5A). These data revealed that ⁶⁸Ga-1 had the highest degree of protein association (92% ± 4%), followed by ⁶⁸Ga-7 (86% ± 2%) and then ⁶⁸Ga-4 (82% ± 7%). Statistical analysis revealed that protein binding of ⁶⁸Ga-1 was significantly different (P value <.05) when compared to that of ⁶⁸Ga-4 and ⁶⁸Ga-7. Differences between protein binding of ⁶⁸Ga-4 and ⁶⁸Ga-7 were not statistically significant (P value >.05). These data are consistent with the heart/blood pool TACs in that increased protein binding correlates with longer blood pool circulation (and consequently, increased delivery and uptake in the LNCaP tumors).

Figure 5.

(A) Percentage ⁶⁸Ga-radioactivity associated with plasma proteins or in solution 15 minutes after injection in mice. (B) High-performance liquid chromatography (HPLC) chromatograms showing the absence of metabolism and single peaks corresponding to ⁶⁸Ga-desferrioxamine B (DFO)-Nsucc-PSMA (⁶⁸Ga-4; blue) and ⁶⁸Ga-DFO-pNCS-Bn-PSMA (⁶⁸Ga-7; red) in the soluble blood component.

The HPLC analysis of the radioactivity in the soluble fraction of the blood pool revealed that both ⁶⁸Ga-4 and ⁶⁸Ga-7 remained 100% intact and chemically unchanged after 15 minutes in mice (Figure 5B). Chemical identity was confirmed by comparison (and spiking) with the isolated ⁶⁸Ga-4 and ⁶⁸Ga-7 radiotracers. Similar to reported data for ⁶⁸Ga-1, these data demonstrated that ⁶⁸Ga-4 and ⁶⁸Ga-7 are metabolically stable in mice.^19,20 Therefore, differences in the tumor uptake, PSMA binding, and pharmacokinetics are not associated with radioactive metabolites.

The PET imaging and ex vivo data provide compelling evidence for the stability, sensitivity, and specificity of these urea-based inhibitors for detecting PSMA expression. It is notable that PSMA binding and pharmacokinetics are both highly sensitive toward changes in the structure of the radiotracer (including the chelate, linker, and spacer used to couple the nuclide to the targeting moiety). These data highlight the importance of the chelate and of optimizing all components of a biological targeting construct to achieve the specific contrast.

Conclusion

Two anti-PSMA urea-based radiotracers incorporating DFO as a chelate for coordinating ⁶⁸Ga³⁺ ions have been synthesized, radiolabeled, and evaluated in a series of in vitro and in vivo experiments. Radiolabeling studies found that ⁶⁸Ga³⁺ can be complexed efficiently and rapidly at room temperature using manual or automated methods that yield formulated radiotracers (⁶⁸Ga-4 and ⁶⁸Ga-7) in high yields, purity, and specific activity suitable for PET imaging. In contrast to the radiosynthesis of the clinical standard ⁶⁸Ga-1, the use of DFO as a chelate instead of HBED for ⁶⁸Ga radiolabeling gives products with a single peak in HPLC. Cellular data (K _d values) showed that ⁶⁸Ga-4 and ⁶⁸Ga-7 displayed lower affinity for PSMA expressed on LNCaP cells than ⁶⁸Ga-1. Dynamic and static PET scans also revealed important differences in the pharmacokinetic profiles of the 3 ⁶⁸Ga-radiotracers. Each radiotracer showed specific binding and high delineation of PSMA-positive LNCaP tumors. However, in comparison to ⁶⁸Ga-1, absolute uptake values in the tumor were ∼10-fold and ∼2.5-fold lower for ⁶⁸Ga-4 and ⁶⁸Ga-7, respectively. In addition, blood pool clearance, kidney retention, and urinary excretion profiles were altered dramatically by changing the chelate and linker/spacer groups. Clearance profiles were found to correlate with both plasma protein binding and measured cellular dissociation constants (K _d values) but not with complex lipophilicity (LogD values). Collectively, these data demonstrate that PSMA binding of small-molecule urea-based inhibitors is particularly sensitive to changes in the entire chemical structure from the targeting moiety, through to the spacer group, linker, and chelate (and likely the chemical nature of the radionuclide) employed in radiotracer design.

Footnotes

Acknowledgments

We thank Dr Henrik Braband, Prof Roger Alberto, Michael Benz, and the Mass Spectrometry Service at the University of Zurich for sample analysis.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Department of Nuclear Medicine, University Hospital Freiburg, the German Cancer Consortium (DKTK), the German Cancer Research Center (DKFZ), the Swiss National Science Foundation (SNSF Professorship PP00P2_163683), and the European Research Council (ERC-StG-2015, NanoSCAN – 676904).

Supplemental Material

Supplementary material for this article is available online.

References

Chang

. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6(suppl 10):S13–S18.

Wright

Jr Grob

Haley

. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48(2):326–334.

Gong

Chang

Watt

. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Mol Urol. 2000;4(3):217–222;discussion 223.

Chen

Foss

Byun

. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem. 2008;51(24):7933–7943.

Srinivasarao

Galliford

Low

. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov. 2015;14(3):203–219.

Hillier

Maresca

Femia

Marquis

. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69(17):6932–6940.

Vallabhajosula

Nikolopoulou

Babich

. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014;55(11):1791–1798.

Banerjee

Pullambhatla

Byun

. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333–5341.

Banerjee

Foss

Castanares

. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51(15):4504–4517.

10.

Banerjee

Foss

Pullambhatla

. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates. J Nucl Med. 2015;56(4):628–634.

11.

Alt

Wiehr

Ehrlichmann

. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate. 2010;70(13):1413–1421.

12.

Benešová

Schäfer

Bauder-Wüst

. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56(6):914–920.

13.

Elsasser-Beile

Wolf

Gierschner

Buhler

Schultze-Seemann

Wetterauer

. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate. 2006;66(13):1359–1370.

14.

Vallabhajosula

Kuji

Hamacher

. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med. 2005;46(4):634–641.

15.

Milowsky

Nanus

Kostakoglu

. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25(5):540–547.

16.

Holland

Divilov

Bander

Smith-Jones

Larson

, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51(8):1293–1300.

17.

Pandit-Taskar

O’Donoghue

, Beylergil V, et al. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(11):2093–2105.

18.

Osborne

Green

Spratt

. A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol. 2014;191(5):1439–1445.

19.

Eder

Schäfer

Bauder-Wüst

. Eisenhut. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688–697.

20.

Eder

Neels

Müller

. Novel Preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel). 2014;7(7):779–796.

21.

Afshar-Oromieh

Avtzi

Giesel

. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209.

22.

Afshar-Oromieh

Malcher

Eder

. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486–495.

23.

Dietlein

Kobe

Kuhnert

. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17(4):575–584.

24.

Kobe

Dietlein

Kuhnert

. The 18F-labeled PSMA_6 compares favorably to 68Ga-labeled PSMA-HBED-CC. A first clinical study in patients with relapsed prostate cancer. J Nucl Med. 2015;56:402.

25.

Weineisen

Schottelius

Simecek

. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56(8):1169–1176.

26.

Rahbar

Ahmadzadehfar

Kratochwil

. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90.

27.

Kozikowski

Zhang

Nan

. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem. 2004;47(7):1729–1738.

28.

Mease

Dusich

Foss

. N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14(10):3036–3043.

29.

Cho

Gage

Mease

. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53(12):1883–1891.

30.

Chen

Pullambhatla

Foss

. Synthesis and biological evaluation of [18F]DCFPyL for PSMA-targeted imaging of prostate cancer. J Nucl Med. 2011;52:294.

31.

Chen

Pullambhatla

Foss

. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17(24):7645–7653. doi: 10.1158/1078-0432.ccr-11-1357.

32.

Banerjee

Pullambhatla

Foss

. ⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem. 2014;57(6):2657–2669.

33.

Afshar-Oromieh

Zechmann

Malcher

. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20.

34.

Kularatne

Zhou

Yang

Post

Low

. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. Mol Pharm. 2009;6(3):790–800.

35.

Maresca

Hillier

Femia

. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52(2):347–357.

36.

Cardinale

Schäfer

Benešová

. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med. 2017;58(3):425–431.

37.

Zanzonico

. Routine quality control of clinical nuclear medicine instrumentation: a brief review. J Nucl Med. 2009;49(7):1114–1131.

38.

Holland

Caldas-Lopes

Divilov

. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PloS One. 2010;5(1):e8859.

39.

Wilson

Jin

Garcia

DaSilva

Houle

. An admonition when measuring the lipophilicity of radiotracers using counting techniques. Appl Radiat Isot. 2001;54(2):203–208.

40.

Waterhouse

. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol. 2003;5(6):376–389.

41.

Kim

Lee

. Performance measurement of the microPET focus 120 scanner. Nucl Med. 2007;48(9):1527–1535.

42.

Loening

Gambhir

. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2(3):131–137.

43.

Kratochwil

Giesel

Leotta

. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med. 2015;56(2):293–298.

44.

Troyer

Beckett

Wright

Jr . Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate. 1997;30(4):232–242.

45.

Ruggiero

Holland

Hudolin

. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med. 2011;52(10):1608–1615.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.45 MB

Radiochemistry and Preclinical PET Imaging of 68 Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen

Abstract

Keywords

Introduction

Materials and Methods

Synthesis

The DFO-Nsucc-PSMA (4)

The DFO-pNCS-Bn-PSMA (7)

Radiochemistry

Radiosynthesis of 68Ga-HBED-CC-PSMA (68Ga-1)

Radiosynthesis of 68Ga-DFO-Nsucc-PSMA (68Ga-4)

Radiosynthesis of 68Ga-DFO-pNCS-Bn-PSMA (68Ga-7)

Lipophilicity (LogD) measurements

Cells and Tissue Culture

Saturation Binding Experiments In Vitro

Xenograft Models

Blood Plasma Protein Binding Studies and Metabolism In Vivo

Small-Animal PET Imaging

Statistical Analyses

Results and Discussion

Synthesis and Radiochemistry

Cellular Assays

Positron-Emission Tomography Imaging in Tumor-Bearing Mice

Plasma Protein Binding and Metabolic Stability

Conclusion

Footnotes

Acknowledgments

Declaration of Conflicting Interests

Funding

Supplemental Material

References

Supplementary Material

Radiosynthesis of ⁶⁸Ga-HBED-CC-PSMA (⁶⁸Ga-1)

Radiosynthesis of ⁶⁸Ga-DFO-Nsucc-PSMA (⁶⁸Ga-4)

Radiosynthesis of ⁶⁸Ga-DFO-pNCS-Bn-PSMA (⁶⁸Ga-7)